BIOMAT Database Logo BIOMAT Database Logo

Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. 2001

R M Gulick, and L M Smeaton, and R T D'Aquila, and J J Eron, and J S Currier, and J G Gerber, and E Acosta, and J P Sommadossi, and R Tung, and S Snyder, and D R Kuritzkes, and R L Murphy, and
Weill Medical College of Cornell University and New York University School of Medicine, Cornell Clinical Trials Unit, New York, NY 10021, USA. rgulick@med.cornell.edu

This prospective, multicenter, open-label study was designed to determine the antiretroviral activity and safety of a 4-drug regimen: 1000 mg indinavir every 8 h with 200 mg nevirapine, 40 mg stavudine, and 150 mg lamivudine, each given twice daily in amprenavir-experienced subjects. The primary end points of the study were the human immunodeficiency virus (HIV) RNA level and CD4 cell count responses. Fifty-six subjects were enrolled and were changed from amprenavir-containing regimens to the 4-drug regimen. Overall, at week 48, 33 (59%) of 56 subjects had HIV RNA levels <500 copies/mL (intent-to-treat analysis, where missing values equal > or =500 copies/mL) and CD4 cell counts increased by 94 cells/mm(3) from baseline. Subjects who had previously taken amprenavir combination therapy were more likely to experience virologic failure than those who had taken amprenavir monotherapy (odds ratio, 7.7; P=.0012). In this study, most subjects who had taken amprenavir-based regimens and who changed to a 4-drug regimen achieved subsequent durable virologic suppression.

UI MeSH Term Description Entries
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002219 Carbamates Derivatives of carbamic acid, H2NC( Carbamate,Aminoformic Acids,Carbamic Acids,Acids, Aminoformic,Acids, Carbamic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D012449 Safety Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property. Safeties

Related Publications

R M Gulick, and L M Smeaton, and R T D'Aquila, and J J Eron, and J S Currier, and J G Gerber, and E Acosta, and J P Sommadossi, and R Tung, and S Snyder, and D R Kuritzkes, and R L Murphy, and
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
July 2000, AIDS (London, England),
R M Gulick, and L M Smeaton, and R T D'Aquila, and J J Eron, and J S Currier, and J G Gerber, and E Acosta, and J P Sommadossi, and R Tung, and S Snyder, and D R Kuritzkes, and R L Murphy, and
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.
August 1998, The Journal of infectious diseases,
R M Gulick, and L M Smeaton, and R T D'Aquila, and J J Eron, and J S Currier, and J G Gerber, and E Acosta, and J P Sommadossi, and R Tung, and S Snyder, and D R Kuritzkes, and R L Murphy, and
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
June 2002, Antimicrobial agents and chemotherapy,
R M Gulick, and L M Smeaton, and R T D'Aquila, and J J Eron, and J S Currier, and J G Gerber, and E Acosta, and J P Sommadossi, and R Tung, and S Snyder, and D R Kuritzkes, and R L Murphy, and
Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection.
December 1999, The Journal of pediatrics,
R M Gulick, and L M Smeaton, and R T D'Aquila, and J J Eron, and J S Currier, and J G Gerber, and E Acosta, and J P Sommadossi, and R Tung, and S Snyder, and D R Kuritzkes, and R L Murphy, and
CD4(+) T Cell Response to Lamivudine, Stavudine and Nevirapine in Human Immunodeficiency Virus Infected Antiretroviral-Naive Men in Nigeria.
December 2011, Indian journal of virology : an official organ of Indian Virological Society,
R M Gulick, and L M Smeaton, and R T D'Aquila, and J J Eron, and J S Currier, and J G Gerber, and E Acosta, and J P Sommadossi, and R Tung, and S Snyder, and D R Kuritzkes, and R L Murphy, and
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
November 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
R M Gulick, and L M Smeaton, and R T D'Aquila, and J J Eron, and J S Currier, and J G Gerber, and E Acosta, and J P Sommadossi, and R Tung, and S Snyder, and D R Kuritzkes, and R L Murphy, and
Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
August 2010, The Pediatric infectious disease journal,
R M Gulick, and L M Smeaton, and R T D'Aquila, and J J Eron, and J S Currier, and J G Gerber, and E Acosta, and J P Sommadossi, and R Tung, and S Snyder, and D R Kuritzkes, and R L Murphy, and
Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection.
February 2002, The Pediatric infectious disease journal,
R M Gulick, and L M Smeaton, and R T D'Aquila, and J J Eron, and J S Currier, and J G Gerber, and E Acosta, and J P Sommadossi, and R Tung, and S Snyder, and D R Kuritzkes, and R L Murphy, and
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
December 2001, Annals of internal medicine,
R M Gulick, and L M Smeaton, and R T D'Aquila, and J J Eron, and J S Currier, and J G Gerber, and E Acosta, and J P Sommadossi, and R Tung, and S Snyder, and D R Kuritzkes, and R L Murphy, and
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
June 2003, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!